Egypt's net foreign reserves rise to $40.2 billion at February-end:    JICA to continue supporting Egypt's educational reforms to boost women's empowerment, gender equality    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    World Bank nods $440 million for enhancing Egypt's railways    Redcon gets an EGP 2.7bn loan from AAIB to complete project at New Alamein    Capital Intelligence confirms Egypt's sovereign ratings with stable outlook    Saudi-led coalition destroys eight Houthi drones: Saudi TV    Egypt condemns latest terror atack in Somalia    Live score: Liverpool v Fulham (English Premier League)    Sisi approves amending law honoring martyrs, victims, missing, injured in terror attacks    Train derails killing 1, injuring 40 in southern Pakistan    Government inaugurates ICT projects in Kafr El-Sheikh    Pope visits Iraq's war-ravaged north on last day of tour    EGX sees strong selling pressure for 5th session straight    Nigeria's Iheanacho, Ghana's Amartey give Leicester win over Brighton    Egypt detects 588 new coronavirus cases, 38 deaths on Saturday    Messi provides 2 assists for Barca ahead of Madrid derby    US envoy seeking support to shakeup Afghan peace process, warring parties object    Al-Sisi, Al-Burhan to intensify efforts towards reaching legally binding GERD agreement    Second large format IKEA Store in Egypt now open at Mall of Arabia    Egypt's Shoukry, UN Secretary-General discuss Ethiopia's Nile dam developments    UK calls on African countries to join UK-Egypt led Adaptation Action Coalition    Al-Sisi visits Sudan for first time after formation of new transitional government    61st Diyarna Exhibition: Showcasing Egyptian Handicrafts    Art House partners with Cultural Development Fund to present theatrical, musical shows    Egypt stresses necessity of launching 'serious' negotiation process to reach deal on GERD before flood season    Egypt, Jordan, and Palestine reiterate call for halting Israeli settlement activities    Egypt clubs protest Football Association decision to cover costs of COVID-19 tests    Yemen's Houthis fire missile at Saudi Aramco site in Jeddah    Messi serves as bright spot in Barcelona's disastrous season    Zamalek ready with striking force against Esperance Tunis    Hassan Allam wins contract to manage, operate Grand Egyptian Museum    Egypt launches ‘Closing the Gender Gap Accelerator' action plan    March: The month of celebrating women    Sudan keen to enhance cooperation with Egypt: Sudanese FM Al-Mahdi    Egypt court upholds 3-year prison sentence for Mubarak-era Minister El-Feky    A Happy Purrfect Rescue Story of 4 Cats in Thailand    Egypt's Zamalek arrive in Tunisia to face Esperance in CAF Champions League    Winston Churchill's Moroccan landscape painting owned by Angelina Jolie sells for $11.5M    Orascom Construction to build Magdi Yacoub Global Heart Centre    Respect for diversity    Huawei launches HUAWEI FreeLace Pro in Egypt with extra-long battery life and top-grade noise cancellation    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    1st hours of registration for coronavirus vaccine seen 7,000 Egyptians signing up: ministry    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Egypt, Ethiopia, Sudan to resume Nile dam talks today    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Pfizer, BioNTech dose first US participants in clinical trials
Trials are researching effectiveness of COVID-19 mRNA vaccine
Published in Daily News Egypt on 06 - 05 - 2020

Pfizer and BioNTech announced on Wednesday that the first US participants have been dosed in the Phase 1/2 clinical trial for the BNT162 vaccine programme to combat the coronavirus (COVID-19).
The trial is part of a global development programme, with the first group in Germany receiving doses last week.
The Phase 1/2 study is looking into the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study.
The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the US will enroll up to 360 healthy subjects into two age cohorts, of 18-55 and 65-85 years of age. The first subjects immunised in Stage 1 of the study will be healthy adults between 18 and 55 years of age.
Older adults will only be immunised with a given dose level of a vaccine candidate once initial testing of that candidate and dose level in younger adults has proven to be safe. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children's Hospital Medical Center will begin enrolment shortly.
"With our unique and robust clinical study programme underway, starting in Europe and now the US, we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most," Pfizer Chairperson and CEO Albert Bourla said. "That we've been able to move from pre-clinical studies to human testing in less than four months is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19."
Pfizer and BioNTech's development programme includes four vaccine candidates, each representing a different combination of mRNA format and target antigen.
The novel design of the trial allows for the various mRNA candidates to be evaluated simultaneously to identify the safest and potentially most effective treatment in a manner that will allow for the real-time sharing of data with regulatory authorities.
"It is encouraging that we have been able to leverage more than a decade of experience in developing our mRNA platforms to initiate a global clinical trial in multiple regions for our vaccine programme in such a short period," said CEO and Co-founder of BioNTech, Ugur Sahin, "We are optimistic that advancing multiple vaccine candidates into human trials will allow us to identify the safest, most effective vaccination options against COVID-19."

Clic here to read the story from its source.